key: cord-0799174-bdcwowci
authors: Monel, B.; Planas, D.; Grzelak, L.; Smith, N.; Robillard, N.; Staropoli, I.; Goncalves, P.; Porrot, F.; Guivel-Benhassine, F.; Demory, N.; Rodary, J.; Puech, J.; Euzen, V.; Belec, L.; Orvoen, G.; Nunes, L.; Moulin, V.; Fourgeaud, J.; Wack, M.; Imbeaud, S.; Campagne, P.; Duffy, D.; Di Santo, J.; Bruel, T.; Pere, H.; Veyer, D.; Schwartz, O.
title: Release of infectious virus and cytokines in nasopharyngeal swabs from individuals infected with non-B.1.1.7 or B.1.1.7 SARS-CoV-2 variants.
date: 2021-05-22
journal: nan
DOI: 10.1101/2021.05.20.21257393
sha: 49f8da3a461032e1ac4aa16171dafa5541ffdaf2
doc_id: 799174
cord_uid: bdcwowci

The mechanisms that allowed for the SARS-CoV-2 B.1.1.7 variant to rapidly outcompete pre-existing variants in many countries remain poorly characterized. Here, we analyzed viral release, anti-SARS-CoV-2 antibodies and cytokine production in a retrospective series of 427 RTqPCR+ nasopharyngeal swabs collected in COVID-19 patients harbouring either non-B.1.1.7 or B.1.17 variants. We utilized a novel rapid assay, based on S-Fuse-T reporter cells, to quantify infectious SARS-CoV-2. With both non-B.1.1.7 and B.1.1.7 variants, viral titers were highly variable, ranging from 0 to >106 infectious units, and correlated with viral RNA levels. Lateral flow antigenic rapid diagnostic tests (RDTs) were positive in 96% of the samples harbouring infectious virus. About 67 % of individuals carried detectable infectious virus within the first two days after onset of symptoms. This proportion decreased overtime, and viable virus was detected up to 14 days. Samples containing anti-SARS-CoV-2 IgG or IgA did not generally harbour infectious virus. The proportion of individuals displaying viable virus or being RDT-positive was not higher with B.1.1.7 than with non- B.1.1.7 variants. Ct values were slightly but not significantly lower with B.1.1.7. The variant was characterized by a fast decrease of infectivity overtime and a marked release of 17 cytokines (including IFN-b, IP-10, IL-10 and TRAIL). Our results highlight differences between non-B.1.1.7 and B.1.1.7 variants. B.1.1.7 is associated with modified viral decays and cytokine profiles at the nasopharyngeal mucosae during symptomatic infection.

SARS-CoV-2 variants have supplanted pre-existing viral strains in many countries. The B.1.1.7 variant, initially detected in UK, displays a 43-90% higher reproduction number than pre-existing variants and is on track to become dominant worldwide 1,2 . The reasons for this increased transmission are not fully deciphered. Proposed mechanistic hypotheses, based on epidemiological modelling, include higher viral loads and longer infectious period, rather than increased susceptibility in children or reduced protection from immunity to pre-existing variants 1, 2 . Little is known about the extent of virus shedding in individuals infected with B.1.1.7. A longitudinal study performed on a limited number of patients (7 individuals were tested) reported that the variant may cause longer infections with similar peak viral RNA concentration compared to non-B.1.1.7 SARS-CoV-2 3 . It has alternatively been observed that B.1.1.7 is associated with higher viral loads than non-B.1.1.7 viruses, as assessed by RT-qPCR 4, 5 . None of these studies examined infectivity of the specimen. Whether B.1.1.7's increased transmissibility is linked to inherent viral properties such as the known increased affinity to ACE2, extended duration of shedding, higher viral peaks, or modifications of the local inflammatory state, remains to be mechanistically determined.

The extent and duration of shedding of infectious virus in nasopharyngeal swabs of patients are only partially characterized. Some studies have corelated RT-qPCR levels, or a positive lateral flow antigenic rapid diagnostic test (RDT), with viral outgrowth assays [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . Assessment of viral infectivity is classically performed using subclones or derivatives of the Vero cell line, which is naturally sensitive to infection and does not mount a type-I Interferon response [6] [7] [8] [9] [10] [11] [12] 16 . In these cells, the presence of replicating virus is generally detected by visualisation of a cytopathic effect after 2-10 days 

We examined the content of nasopharyngeal swabs from RT-qPCR+ COVID-19-diagnosed individuals with four different assays (Fig. 1a) . We assessed SARS-CoV-2 antigenic reactivity with a lateral flow antigen rapid diagnostic test (RDT) (from SD Biosensor Inc). We measured anti-SARS-CoV-2 IgG and IgA with the sensitive flow-cytometry based S-Flow assay 17 . In a subset of 202 samples, we measured the levels of 48 cytokines, by either a bead-based multiplexed immunoassay system Luminex or the digital Elisa Simoa 18 . We also titrated infectious virus with the S-Fuse assay 19, 20 . S-Fuse cells are U2OS cells stably expressing ACE2 and including the GFP-Split complementation system 21 , producing GFP upon cell-cell fusion. The total area of syncytia, measured at 20h post infection with a high-content imager, correlates with the viral inoculum, indicating that the assay provides a quantitative assessment of viral infection 20 . We improved the sensitivity of viral detection by stably expressing TMPRSS2, a surface serine protease known to enhance infection, in the cells, yielding S-Fuse-T cells. We first tested 12 RT-qPCR negative and 17 RT-qPCR positive nasopharyngeal swabs (Fig.   1b) . The negative samples did not generate a GFP signal. Serial dilutions of RT-qPCR positive specimen demonstrated substantial heterogeneity in infectivity (from 0 to 10 5-6 Infectious Units (IU)/ml).

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Limiting dilutions of 20 nasopharyngeal swabs demonstrated that S-Fuse-T cells were similarly sensitive to Vero E6 cells (assessed by the cytopathic effect generated at 5 days pi) to detect viral infectivity, with a strong correlation between the two assays (Fig. 1b) . A representative experiment with two positive samples is depicted in Fig. 1c . Of note, viral release in the supernatant of S-Fuse-T infected cells reached only 10 3 pfu/ml, probably because the cells rapidly die upon infection.

We counterstained fixed plates with mab48, a human neutralizing monoclonal antibody targeting the SARS-CoV-2 Receptor Binding Domain (RBD) of the Spike, which does not cross-react with seasonal coronaviruses 20 . The GFP+ cells also expressed the Spike (Fig. 1d) , indicating that they have been productively infected with SARS-CoV-2 and not with another respiratory virus that may have triggered syncytia formation. Moreover, pre-incubation of the nasopharyngeal swabs with mab48 neutralized infection and inhibited the GFP+ signal, confirming that S-Fuse-T cells assayed infectious SARS-CoV-2 ( Fig. 1e) . Thus, S-Fuse-T cells provide a rapid system to detect infectious SARS-CoV-2 in nasopharyngeal swabs.

We screened two series of nasopharyngeal swabs from RT-qPCR diagnosed COVID-19

individuals. Samples were collected at Hôpital Européen Georges Pompidou (Paris, France) for diagnostic purposes and further analyzed in accordance with local ethical standards. The biological (age and sex) and clinical (disease severity and days POS) parameters of the individuals are depicted We titrated viral infectivity in the first series of 200 patients. 107 patients (53%) harboured detectable viable virus in their nasopharyngeal swabs (Fig. 2a) . The infectious titers were highly variable, ranging from 0 to >10 6 IU/ml. To further characterize these variations, we plotted Ct values, days POS and levels of anti-SARS-CoV-2 IgG or IgA for each individual (Fig. 2a) . Data were ranked from high to low infectious titers in RDT + and RDT-categories. The RDT-category was then ranked from low to high levels of SARS-CoV-2 IgG. There was a strong inverse correlation between infectious titers and viral RNA levels, defined by the Ct value (Fig. 2b) . The median titer within positive individuals was . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 22, 2021. ;  https://doi.org/10.1101/2021.05.20.21257393 doi: medRxiv preprint 10 3 IU/ml (Fig. 2c) . The antigenic RDT was positive in 93% of samples with viable virus (Fig. 2a,c) . We also identified a fraction of individuals without detectable viable virus that were RDT-positive (23%).

This allowed us to estimate the sensitivity of 93% (95% CI: 86 to 96) and specificity of 78% (95% CI: 68 to 85) of the RDT to detect infectious samples in this cohort. As expected, samples positive in the infectivity assay displayed lower Ct values (median: 22) than negative samples (median 31.3) (Fig. 2d ).

This represents a 630-fold (=2 9.3 ) increase in viral RNA levels associated with viral infectivity. The highest viral titers (>10 5 ) corresponded to Ct values < 22. The median time of infectious virus shedding was 2 days (range -3 to 14 days, IQR 1 to 4 days). 67% of individuals displayed infectious virus 0 to 2 days POS. Specific antibodies started to be detected at 5-10 days POS in nasopharyngeal swabs, with some exceptions. There was a clear dichotomy between the detection of infectious virus and the presence of anti-SARS-CoV-2 IgG or IgA antibodies (Fig. 2a,b) . This strongly suggests that the antibodies locally present in nasopharyngeal secretions can neutralize viral infectivity. These results further support previous reports indicating that infectious SARS-CoV-2 could only be isolated in individuals with low or undetectable neutralizing antibodies in their serum 11, 12 . We did not have access to serum samples in this cohort to compare levels of mucosal and circulating antibodies. (Fig. 3d) . The median time of infectious virus shedding was 2 days POS with both viruses (range -1 to 10 days) (Fig. 3e) . Anti-SARS-CoV-2 IgG or IgA were not detected in nasopharyngeal swabs carrying viable virus, with a few exceptions (Fig. 3e) . Overall, these results indicate that there is no . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 22, 2021. ; https://doi.org/10.1101/2021.05.20.21257393 doi: medRxiv preprint significant difference between the two viral groups regarding the various parameters, when analyzed globally.

We then evaluated by a multivariate analysis (partial least square regression) the associations between infectious titers and other parameters (Fig. 4a) . The characteristics associated with detection of viable virus were RDT positivity, low Ct values, early time since onset of symptoms, absence of IgG or IgA antibodies. There was no association between detection of viable virus and disease severity, age or sex of the individuals (Fig. 4a) samples. Examples of increased cytokines, including IFN-b, IP-10, IL-10, and TRAIL are depicted in Fig.   5a . Other cytokines, such as IFNa2, IL-6, IL-17a and TNFa were non significantly elevated (Fig. 5a) . The full set of results appear in Fig. S1 . Moreover, there was a strong negative correlation between Ct values and levels of a few cytokines, such as IFNa2 (Fig. 5b) . This correlation was observed with both non-B.1.1.7 and B.1.1.7 variants. This was not the case for other cytokines, such as IL-6 ( Fig. 5b) .

These results strongly suggest that B.1.1.7 infection may cause higher inflammatory and interferon responses.

We then established a two-by-two correlation table of all virological and immunological parameters that were measured in the second cohort, independently of the viral variant (Fig. S2 ).

values negatively correlated with the levels of IFNa2, as depicted in Fig. 5a , and with GRO-B, but not with any other cytokines. There were strong correlations between most of the up-regulated cytokines, suggesting that similar pathways of activation drove their production (Fig. S2 ).

We measured infectious SARS-CoV-2 in nasopharyngeal swabs with a novel cell reporter system termed S-Fuse assay, that we improved by adding TMPRSS2 19, 20 . The technique is based on the detection of GFP+ syncytia formed between infected and neighbouring cells. The assay is rapid, and infectivity is revealed in less than 24h. It is semi-automated and less labour intensive than classical Vero cells 11 . This strongly suggests that the S-Fuse assay is particularly sensitive to detect viable virus.

We report a strong correlation between detection of viable virus, and RDT positivity or low Ct values. About 95% of samples carrying infectious virus were RDT+ and displayed Ct values <22.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 22, 2021. ; https://doi.org/10.1101/2021.05.20.21257393 doi: medRxiv preprint Therefore, these two parameters are reliable markers of the presence of infectious virus, at least before the appearance of SARS-CoV-2 antibodies. Despite evidence of prolonged viral RNA shedding in some specimen (up to 28 days), viable virus detection was rather short lived in our study. The low amounts of viral RNA released on the long-term thus likely corresponds to viral remnants rather than to infectious virus. The samples carried viable virus mostly within the first 10 days, with a median of 2-3 days POS and occasional detection up to 14 days. In other reports, no live virus was detected in respiratory samples after 8-9 days of symptoms, probably reflecting the lower sensitivity of Vero cellbased assays 7-9,13,32,33 . Of note, shedding of infectious virus up to 20 days in one severe COVID-19 case and 70 days in one immunocompromised patient has also been reported 6, 34 .

The extended detection of viable virus reported here suggests that the contagiousness period can be slightly longer than previously thought, at least for some individuals. This may have important implications for viral transmission in a community or hospital setting. Moreover, our results confirm that the antigenic test has a better positive predictive value than a RT-qPCR test for the potential contagiousness of a given individual 15 .

We then compared the virological and immunological characteristics of nasopharyngeal unclear. This may suggest that infectivity peaked earlier, before onset of symptoms. It is also possible that some cytokines modulate infectivity of the samples. An analysis performed on a larger number of symptomatic and asymptomatic individuals will help determining whether B.1.1.7's increased transmissibility is associated with extended or higher shedding of viral RNA after onset of symptoms, as reported in recent studies [3] [4] [5] 35 . The differences between viral lineages were however minimal in some of these studies. Future work is also warranted to assess viral loads in asymptomatic B.1.1.7infected individuals.

We report here a main difference between B. Our study has some limitations. We did not analyse longitudinal samples and the number of samples collected at late time points (after day 10) was scarce. We also did not assess systemic immune responses, since we did not have access to the blood samples of the same individuals. It will be worth determining whether the oral cavity and saliva, important sites for SARS-CoV-2 transmission 38 , carry different levels of variants. Future work with higher numbers and types of specimen and serial sampling will help further characterizing the virological and immunological determinants of viral transmission. It will be also of great interest to analyze these parameters in asymptomatic and pre-symptomatic individuals, who play a prominent role in viral spreading at the population level. 

No statistical methods were used to predetermine sample size. The experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment.

Our research complies with all relevant ethical regulation.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Republic of Korea) was used on transport media according to the manufacturer's recommendations.

S-Fuse assay. U2OS-ACE2 GFP1-10 or GFP 11 cells, also termed S-Fuse cells, become GFP+ when they are productively infected by SARS-CoV-2 19, 20 . TMPRSS2 was added in S-Fuse cells as described, yielding S-Fuse-T cells 19 . Cells were tested negative for mycoplasma. Cells were mixed (ratio 1:1) and plated at 8x10 3 per well in a μClear 96-well plate (Greiner Bio-One). The nasopharyngeal swabs or a SARS-CoV-2 strain control were added to the S-fuse cells at serial dilutions from 1:10 to 1:1 000 000. 18 hours later, cells were fixed with 2% PFA, washed and stained with Hoechst (dilution 1:1,000, . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 22, 2021. ; https://doi.org/10.1101/2021.05.20.21257393 doi: medRxiv preprint Invitrogen). Images were acquired with an Opera Phenix high content confocal microscope (PerkinElmer). The GFP area and the number of nuclei were quantified using the Harmony software (PerkinElmer). The viral titer (Infectious units /mL) was calculated from the last positive dilution with 1 infectious unit (IU) being 3 times the background (GFP area in non-infected controls).

S-Flow Assay. The S-Flow assay was performed as described 17, 39 . Briefly, HEK-293T (referred as 293T) cells were acquired from ATCC (ATCC® CRL-3216TM) and tested negative for mycoplasma. 293T Cells stably expressing Spike or control cells were transferred into U-bottom 96-well plates (10 5 cells/well). 

recognizes the RBD 20 . SARS-CoV-2 isolate (Wuhan) was used as a positive control as described 19 20 .

Nasopharyngeal samples were inactivated with Triton X-100 1% (v/v) for 2h at RT, and cytokines were quantified as described 18 . IFNa2, IFNg, IFNl3, IL-17A were quantified with Simoa assays developed as described with Quanterix Homebrew kits 40 . Other cytokines and chemokines were measured with a commercial Luminex multi-analyte assay (Biotechne, R&D system). Titration of infectious SARS-CoV-2 in the swabs. Left panel: Titration was performed with S-Fuse-T cells, which become GFP+ after infection. S-Fuse-T cells were exposed to serially diluted swabs (10 -1 to 10 -5 ) or to purified viral stocks (red dots) as a control. 12 RT-qPCR-(white dots) and 17 RT-qPCR+ (black dots) samples were first analyzed. An infectious titer was calculated in Infectious Units (IU)/ml, after automatic scoring of the area of GFP+ cells at each dilution. Right panel: correlation between titers measured in Vero cells (in DCP50/ml) and S-Fuse-T cells (in IU/ml). c. Representative images of S-Fuse-T cells exposed to the indicated dilutions of nasopharyngeal swabs. Samples from one non-B.1.1.7-infected and one B.1.1.7-infected individuals are shown. Scale bar: 400 µm. d. GFP (green) and S (red) expression in S-Fuse-T cells exposed to one infectious swab analyzed by immunofluorescence. The Hoechst dye (blue) stains the nuclei. Scale bar: 40 µm. e. Neutralization of infectious virus by mAb48. Swabs (n=19) were preincubated 30 min at RT with mAb48 (1 µg/ml) and added to S-Fuse-T cells. Result from one representative experiment out of 3 is shown. A Wilcoxon paired t-test was performed **** p<0.0001. S1 (related to Fig. 5). Cytokines production in swabs from non-B.1.1.7 and B.1.1.7 Table S1 . Characteristics of the individuals with PCR-confirmed SARS-CoV-2 infection.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 22, 2021. ; https://doi.org/10.1101/2021.05.20.21257393 doi: medRxiv preprint

Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7

Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England

Densely sampled viral trajectories suggest longer duration of acute infection with B.1.1.7 variant relative to non-B.1.1.7 SARS-CoV-2. medRxiv

S-variant SARS-CoV-2 lineage B1.1.7 is associated with significantly higher viral loads in samples tested by ThermoFisher TaqPath RT-qPCR

Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study. The Lancet Infectious Diseases

Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with

Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility

Virological assessment of hospitalized patients with COVID-2019

Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards

SARS-CoV-2 detection, viral load and infectivity over the course of an infection

Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19)

Shedding of infectious SARS-CoV-2 from airways in hospitalized COVID-19 patients in relation to serum antibody responses. medRxiv

Predicting Infectious Severe Acute Respiratory Syndrome Coronavirus 2 From Diagnostic Samples

Comparative performance of SARS CoV-2 lateral flow antigen tests demonstrates their utility for high sensitivity detection of infectious virus in clinical specimens. medRxiv

Antigen-Based Testing but Not Real-Time Polymerase Chain Reaction Correlates With Severe Acute Respiratory Syndrome Coronavirus 2 Viral Culture

CoV-2: the viral shedding vs infectivity dilemma

A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations

Distinct systemic and mucosal immune responses to SARS-CoV-2. medRxiv

Syncytia formation by SARS-CoV-2 infected cells

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

IFITM proteins inhibit placental syncytiotrophoblast formation and promote fetal demise

Clustering and superspreading potential of SARS-CoV-2 infections in Hong Kong

Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study

Just 2% of SARS-CoV-2-positive individuals carry 90% of the virus circulating in communities. medRxiv

Dufloo for discussion and critical reading of the manuscript. We thank AGEPS, Assistance Publique -Hôpitaux de Paris, for providing the RDTs. We thank the patients who participated in the study, the